
The Biological Infrastructure Rewrite: CRISPR, AI, and the End of Pharmacological Management
The convergence of FDA-approved in-vivo CRISPR therapies, NIH's AI funding reallocation, and breakthroughs in 3D-bioprinted tissues signals a structur...
Read Full Story →




